Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group-Reference-Cited by-同舟云学术

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

Published:2024-07 Issue:7 Volume:35 Page:588-606
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mosele M.F.^ORCID,Westphalen C.B.^ORCID,Stenzinger A.,Barlesi F.,Bayle A.,Bièche I.,Bonastre J.,Castro E.,Dienstmann R.,Krämer A.,Czarnecka A.M.,Meric-Bernstam F.,Michiels S.,Miller R.,Normanno N.,Reis-Filho J.,Remon J.,Robson M.,Rouleau E.,Scarpa A.,Serrano C.,Mateo J.,André F.

Funder

European Society for Medical Oncology

Publisher

Elsevier BV

Reference193 articles.

1. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group;Mosele;Ann Oncol,2020

2. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials;Hong;Lancet Oncol,2020

3. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors;Demetri;Clin Cancer Res,2022

4. FDA Approval Summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors;Marcus;Clin Cancer Res,2019

5. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial;Subbiah;Lancet Oncol,2022

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preserving momentum on next-generation sequencing for head and neck squamous cell carcinoma;Annals of Oncology;2024-10

2. Combination ofBRCAdeep targeted sequencing and shallow whole genome sequencing to detect homologous recombination deficiency in ovarian cancer;2024-09-10

3. Addressing the knowledge gap in the genomic landscape and tailored therapeutic approaches to adolescent and young adult cancers;ESMO Open;2024-08

4. Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial;Annals of Oncology;2024-08

5. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer;International Journal of Molecular Sciences;2024-07-19